GlassScriptPhysician profile
Manav K Salwan
NPI 1457424301
$9,752.91
in general payments reported to CMS, 2019-2025
49 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $1,530 · 2021: $1,317 · 2022: $1,017 · 2023: $1,262 · 2024: $1,638 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,700.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,603.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,182.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $842.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $746.22 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $654.44 | 2019-2023 | |
| Glaxosmithkline, LLC. | $529.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.29 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $401.56 | 2019-2025 | Veozah |
| Pfizer INC. | $400.29 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $286.58 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $232.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $221.49 | 2019-2024 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $188.59 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $180.70 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $150.11 | 2019-2023 | Steglujan, Steglatro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manav Salwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.